NTx Bio News and Activities

View the org chart displaying its 25 main executives

Most searched biographies at NTx Bio

• Joan Haab, Chief Executive Officer and Director
• David Seldin, Director
• Thomas Nickoloff, Director

Popular executive movements at NTx Bio

• Joan Haab, who was Chief Operations Officer, is promoted to Chief Executive Officer and Director  (posted on January 8 2026).
• James Coffin, Chief Executive Officer and Director, has left the company  (posted on January 8 2026).
• Dave Johnson has joined the company as Director  (posted on October 1 2025).

Create your alert
to follow the executive moves at NTx Bio.

NTx Bio has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
• Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by NTx Bio

• NTx Bio Appoints Dr. Joan Haab as Chief Executive Officer
• NTx Appoints Veteran Corporate Strategist Dave Johnson to Board of Directors
• NTx Expands Scientific Advisory Board with Appointment of RNA Biology Pioneer Dr. Jeff Coller
• News (3)
• Governor Abbott Announces NTxBio Facility In Plano
• NTx Establishes Scientific Advisory Board with Distinguished Leaders in Oncology
• NTx Appoints Seasoned Biotech Executive Joan Haab as Chief Operations Officer
• NTx Welcomes Accomplished Government Industry Executive William Doak as Vice President of Global Government Programs
• NTx Announces Full Commercial Availability of NTxscribe to Broadly Enable RNA Therapies
• NTx Secures $15M in Venture Debt from J.P. Morgan to Fuel Expansion of Next-Generation Biomanufacturing Solutions
• View more press releases Close

Social media about NTx Bio

• NTx Bio on Wikipedia, Google News & Yahoo Finance
• NTx Bio on LinkedIn, X (Twitter) & YouTube